Results 181 to 190 of about 756,756 (215)

Induction of Protective Serum Meningococcal Bactericidal and Diphtheria-Neutralizing Antibodies and Mucosal Immunoglobulin A in Volunteers by Nasal Insufflations of theNeisseria meningitidisSerogroup C Polysaccharide-CRM197 Conjugate Vaccine Mixed with Chitosan

, 2005
Zhiming Huo, Ruchi Sinha, Edel A. McNeela, Ray Borrow, Rafaela Giemza, Catherine Cosgrove, Paul T. Heath, Kingston H. G. Mills, Rino Rappuoli, George E. Griffin, D. J. Lewis   +10 more
openalex   +1 more source

Capsular Polysaccharide as a Potential Target in Hypervirulent and Drug-Resistant <i>Klebsiella pneumoniae</i> Treatment. [PDF]

Infect Drug Resist
Ke Y, Zeng Z, Liu J, Ye C.
europepmc   +1 more source

Vaccinations in Pediatric Hematology and Oncology: Biologic Basis, Clinical Applications, and Perspectives. [PDF]

Vaccines (Basel)
Martire B, Beni A, Mastrototaro MF, Santilli V, Ottaviano G, Montin D, Rizzo C, Sgrulletti M, Miraglia Del Giudice M, Costagliola G, Moschese V, Italian Society of Pediatric Allergology and Immunology (SIAIP) Vaccine Committee.   +11 more
europepmc   +1 more source

Chrono-optimizing vaccine administration: a systematic review and meta-analysis. [PDF]

Front Public Health
Vink K, Kusters J, Wallinga J.
europepmc   +1 more source

Host-Pathogen Interaction Interface: Promising Candidate Targets for Vaccine-Induced Protective and Memory Immune Responses. [PDF]

Vaccines (Basel)
Guerrero GG, Madrid-Marina V, Martínez-Romero A, Torres-Poveda K, Favela-Hernández JM.   +4 more
europepmc   +1 more source

Progress in the development of an Advax-adjuvanted protein capsular matrix vaccine against typhoid fever. [PDF]

Microbe Immun
Petrovsky N, Killeen KP.
europepmc   +1 more source

Vaccination for prevention of hearing loss: a scoping review. [PDF]

Commun Med (Lond)
Johri M, Téhinian S, Pérez Osorio MC, Barış E, Wahl B.   +4 more
europepmc   +1 more source

Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. [PDF]

Vaccines (Basel)
Omole T, Pelayo E, Weinberg AS, Chalkias S, Endale Z, Tamms G, Sterling TM, Good L, Shekar T, Johnson M, Banniettis N, Buchwald UK, Esteves-Jaramillo A.   +12 more
europepmc   +1 more source

A dynamic transmission model for assessing the impact of pneumococcal vaccination in the United States. [PDF]

PLoS One
Malik TM, Bakker KM, Oidtman RJ, Sharomi O, Meleleo G, Nachbar RB, Elbasha EH.   +6 more
europepmc   +1 more source